Envonalkib (CT-707)
ALK-positive Non-Small Cell Lung Cancer
Phase 3NDA Submitted
Key Facts
Indication
ALK-positive Non-Small Cell Lung Cancer
Phase
Phase 3
Status
NDA Submitted
About CSPC Innovation Pharmaceutical
CSPC Innovation Pharmaceutical's mission is to establish CSPC as a global, innovation-driven biopharmaceutical leader by developing and commercializing novel therapeutics. Its key achievement is building a substantial and maturing clinical pipeline, primarily in oncology, which is now advancing into late-stage trials and contributing to the parent group's valuation of over $45 billion. The strategy centers on leveraging internal R&D across multiple modalities, strategic external partnerships, and the parent company's formidable commercial and manufacturing scale to efficiently bring differentiated medicines to the large Chinese and international markets.
View full company profile